VPT:CC - Ventripoint to Demonstrate AI-powered Heart Imaging Technology at The British Congenital Cardiac Association Annual Conference
(TheNewswire)
Toronto, Ontario – TheNewswire - November 09, 2023 -Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), (TSXV:VPT ) ( OTC:VPTDF) is thrilled to announce itwill be showcasing its AI-powered heart-imaging technology at theBritish Congenital Cardiac Association (BCCA) Annual Conference thisyear in Bristol, UK from Nov. 13 th to Nov.14 th .
As a Gold Level Sponsor, Ventripoint will have adesignated booth for in-person demonstrations that will allowattendees to observe the VMS+ system in real-time, using AI to obtainMRI-equivalent cardiac metrics from ultrasound images.
“Ventripoint is looking forward to the exchange ofideas and demonstrating our diagnostic technology to otherprofessionals in the echocardiography and cardiac field”, saidAlvira Macanovic, Ventripoint’s President and CEO. “Our goal is tocontinue expanding Ventripoint’s adoption in hospitals and clinicsaround the world.”
The BCCA supports and represents medical practitionersin the practice or research of congenital heart disease. The BCCAattracts over 300 delegates worldwide, including cardiologists andsonographers focused exclusively on congenital heart defects inchildren and adults.
Ventripoint will also be joined by its UKrepresentatives from Cardiologic, who specialize in medical devices inthe cardiology field. This will give attendees the opportunity toconnect with Cardiologic, which has extensive experience working withcardiologists, cardiac surgeons, and technicians.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson
416-669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.